Lymphoma is not curable. However, due to improvements in treatment, patients are probably benefiting from their lymphomas. As the disease progresses, the chances of cure decrease.
Standard chemotherapy for solid tumors and aggressive chemotherapy regimens may be used as a general standard treatment, although results are usually worse than those obtained with the standard chemotherapy regimen alone. Radiation therapy and targeted agents may be used in addition to chemotherapy to augment treatment, although results are also worse than with chemotherapy alone. The best results are often obtained when treatments used at other sites are combined with chemotherapy. In addition to these conventional treatments, the use of immunotherapy has resulted in good clinical results when combined with conventional therapies.
Immunocompromised patients do not have a higher risk of B-cell lymphoma as compared to immunocompetent patients. Conversely, the disease is rare in immunocompetent subjects under the age of 20 years old, but increased from age 40 years onwards.
B-cell lymphoma manifests as a slow decline in lymph node function or mass (a'slowly progressive disease'). A fastly progressive disease course, for example, in the context of [acute lymphoblastic leukemia](https://www.withpower.com/clinical-trials/acute-lymphoblastic-leukemia) or other leukemias, will also indicate this diagnosis. In both case scenarios, imaging is helpful if the cause of the persistent lymphadenopathy remains unclear. In lymphoma, specific imaging techniques such as positron emission tomography for Hodgkin's disease and single-photon emission computed tomography for diffuse large B-cell lymphoma will detect disease activity.
While lymphoma is a disease that forms malignant tumors in the lymphatic system, it is a very heterogeneous disease with no general diagnostic standard. As a result, there are many subtypes that have different clinical and histopathological characteristics but the same disease biology.\n
Around 32,000, 13,000, 6,950, 4,280, 3,260 and 3,260 people in the United States are believed to get lymphoma, B-cell, follicular, mantle zone-cell, Burkitt, and B-cell, Hodgkin/Reed/Richardson-Siemsek B, subtypes, a year, respectively.
For patients receiving venetoclax, the vast majority of respondents (96% of respondents) experienced adverse events ranging from mild-moderate to moderate or severe (that caused them to stop or change drug). These events were predominantly local or gastrointestinal but also included hematological, skin, or central nervous system side effects.
New drugs have been in development for many years, and many of them are being used to treat lymphoma, b-cell. Still, patients with an aggressive type of lymphoma, like DLBCL, continue to resist effective treatment. The discovery that B7-H3 might be useful in lymphoma may present the chance for the creation of new treatment strategies for these malignancies.
Recent research is mainly focussing on developing effective chemotherapy treatments. There are also trials looking for immunotherapeutic treatments and targeted therapies for lymphoma. There have also been trials for other types of tumours such as brain tumours, [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer)s, lung cancers, liver cancers, and others. These are being used to investigate possible effective treatments. There are some treatments and therapies for other cancers in the early stages of research or are being used to increase our understanding of lymphoma. Because these cancers usually affect adults and it is hard to find statistics for lymphoma in small children, it is difficult to find out whether or not the amount of research on this type of cancer is low and could become an important health care issue.
Recent advances in understanding the molecular basis of B-cell malignancies have brought about the development of new therapeutic approaches. In particular studies have highlighted the importance of TNF-R1 inhibition for the treatment of lymphomas and other B-cell malignancies. On this basis, recent clinical trials have focused on the optimization of venetoclax doses, pharmacokinetics and the evaluation of novel combinations for therapeutic use as well as for testing antitumor activity and other immunomodulatory properties. The drug's role as a key component of B-cell malignancy treatment is further highlighted by the development of a clinical trial for venetoclax as a single agent treatment in patients with relapsed chronic lymphocytic leukemia.
In this phase III clinical trial of people with early follicular or advanced follicular non-Hodgkin's lymphoma, venetoclax met its primary analysis endpoints. Venetoclax was generally well tolerable, but its side effects were more frequent in the older populations. Longer periods and higher doses of interstitial fluid were associated with an increased risk of serious venetoclax-related adverse events.
Clinical responses were observed in patients with lymphomas as well as other malignancies. This suggests that venetoclax has the ability to produce responses in some hematopoietic cancers. Some of these observations in patients may indicate that venetoclax will be effective in other types of cancer because of its ability to impact the function of hematopoietic cells in the body.